Steger, GG; Greil, R; Samonigg, H; Jakesz, R; Bartsch, R; Mlineritsch, B; Melbinger-Zeinitzer, E; Marth, C; Schippinger, W; Gnant, MF.
An interim safety analysis of ABCSG-24: 6 cycles of docetaxel, epirubicin, and capecitabine plus pegfilgrastim (DEC) vs. 6 cycles of docetaxel and epirubicin plus pegfilgrastim (DE) in the neoadjuvant treatment of operable breast cancer.
BREAST CANCER RES TREAT. 2006; 100: S156-S156.
[Poster]
Web of Science